{"analyses":[{"ciLowerLimit":"0.98","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.61","groupDescription":"Comparison of EGFR positive populations","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0662","paramType":"Hazard Ratio (HR)","paramValue":"1.26","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.61","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.69","groupDescription":"Comparison of EGFR negative populations","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9403","paramType":"Hazard Ratio (HR)","paramValue":"1.02","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"12.6","value":"8.9"},{"groupId":"OG001","lowerLimit":"6.1","upperLimit":"7.3","value":"6.3"}]}],"title":"EGFR Positive (n=149,143)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"14.7","value":"11.5"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"12.0","value":"6.7"}]}],"title":"EGFR Negative (n=39,32)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"EGFR is a gene in the tumor tissues and mutations in this gene have been linked to a variety of tumors. Presence or absence of EGFR was determined by IHC. PFS was defined as time from randomization to the date of documented disease progression or death, whichever occurred first in EGFR positive and negative populations. Participants without progression were censored at the date of last tumor assessment where non progression was documented. If a participant receives a second anti-cancer therapy without prior documentation of disease progression, the participant was censored at the date of last tumor assessment before starting new chemotherapy. Kaplan-Meier estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either pemetrexed 500 mg/m\\^2 every 21 days until disease progression, unacceptable toxicity or death or docetaxel 75 mg/m\\^2 every 3 weeks until disease progression, unacceptable toxicity or death. Choice of comparator was left to the discretion of the investigator in countries where both treatments are registered to use and are commercially available for second line use (otherwise, docetaxel was administered), assigning the participant to either comparator depending upon the medical needs of the participant. Participants were required to receive concomitant treatment therapy as indicated in the product label.","id":"OG000","title":"Comparator"},{"description":"Participants received erlotinib, 150 mg, administered orally as a tablet, once daily until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Erlotinib"}],"paramType":"MEDIAN","populationDescription":"FAS population; Only Participants with confirmed status of EGFR were included in the analysis; number of participants who were EGFR positive or negative","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 and Every 12 Weeks until Disease Progression or unacceptable toxicity or Until Data Cut off (07 September 2010) up to 52 months","title":"PFS in EGFR Positive and Negative Population (Data Cutoff 07 September 2010)","type":"SECONDARY","unitOfMeasure":"weeks"}